FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas by Mann, B et al.
The Fas molecule (CD95) is constitutively expressed on macro-
phages and neutrophils and, after activation, also on NK, T and B
cells. Most of these cells also express FasL after activation
(reviewed in Walker et al, 1997). Cross-linking of Fas with FasL
results in apoptosis of these cells, thus preventing their overgrowth
and maintaining the immunological homeostasis. Similarly, acti-
vated CTLs (cytotoxic T cells) use FasL not only as a cytotoxic
effector mechanism to induce apoptosis in Fas-expressing targets
(Oshimi et al, 1996), but possibly for an autocrine suicide once
the CTLs have eliminated the antigen (Brunner et al, 1995; Dhein
et al, 1995). Further, FasL expressed in some peripheral tissues
such as testis or the anterior eye chamber induces apoptosis in acti-
vated lymphocytes that infiltrate these sites, thus protecting them
from immune reaction (￿immune privilege￿) (Bellgrau et al, 1995;
Griffith et al, 1995). In several other tissues, such as liver, skin and
the colon, FasL may be involved in other cellular processes, e.g.
regulation of physiological cell turnover (Galle et al, 1995; French
et al, 1996 a,b; Hahne et al, 1996; Walker et al, 1997).
Colorectal carcinoma (CRC) cells were recently reported to
express FasL (O￿Connell et al, 1996). Co-culture experiments
have shown that these cells as well as FasL+ carcinoma cells of
several other tissues are able to induce apoptosis in Jurkat cells
(reviewed in Walker et al, 1997). These in vitro experiments, in
which Jurkat cells are used as model T cells, are the basis for the
hypothesis that, also in vivo, the FasL expression on tumour cells
might enable them to evade immune destruction by inducing apop-
tosis in CTLs (Nagata and Golstein, 1995). The detection of FasL
mRNA and protein in the tissue of carcinomas of the lung
(Niehans et al, 1997), liver (Strand et al, 1996), skin (Hahne et al,
1996) and colon (Shiraki et al, 1997) supports the concept of a
FasL-mediated immune escape of tumour cells.
In vivo model studies have led, however, to somewhat diverging
conclusions. In a mouse model, FasL+ melanoma cells rapidly
formed tumours in Fas+ mice, whereas tumour growth was delayed
in Fas— lpr— mutant mice, in which immune effectors cannot be
killed by FasL (Hahne et al, 1996). On the other hand, gene
transfer of FasL into tumour cells was shown to inhibit tumour
growth in a mouse model by two mechanisms: either by inducing
apoptosis in Fas+ carcinomas or by inducing potent inflammatory
reactions in Fas— carcinomas (Arai et al, 1997).
If FasL expression indeed confers a selective advantage on
colon carcinoma cells, one could hypothesize that the FasL+
tumour cell variants are overrepresented in metastatic tissue as a
result of successful immune escape during migration and coloni-
zation of the distant organs. This notion is supported by the recent
investigation of four liver metastases in which the detection of
FasL by RT-PCR was more frequent (4/4) than in a group of six
primary CRCs (2/6) (Shiraki et al, 1997).
The analysis of the situation in vivo, however, is complicated by
the fact that FasL may be expressed on tumour cells as well as on
activated T cells. In the normal colonic mucosa, about 10% of
T cells are activated and this fraction increases in primary CRC
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SummaryColorectal carcinoma cells have recently been shown to express Fas ligand (FasL). This ligand could allow the tumour cells to
evade activated tumour-infiltrating lymphocytes (TILs) by inducing their apoptosis and would thus promote tumour survival and possibly
metastasis formation. To test this hypothesis in vivo we analysed the expression of FasL mRNA and protein in paired tissue samples of
normal colonic mucosa (N), primary colorectal carcinomas (T) and their metastases (M) from a total of 21 patients by four different methods.
Additionally, the presence and activation status of infiltrating lymphocytes, which might contribute to the total amount of FasL in the tissue,
was determined by semiquantitative reverse transcription–polymerase chain reaction (RT–PCR) in the same samples. The frequency of FasL
detection was 30–40% in T and was 60–100% in M, depending on the sensitivity of the method. Simultaneously, the amount of CD25 mRNA,
used as a measure of the number of activated TILs, was in 90% of patients lower in M than in T. The increased frequency of FasL detection
in liver metastases was therefore not due to the presence of activated TILs. We conclude that metastasizing subpopulations of colorectal
tumour cells express FasL more frequently than the primary carcinomas and may be able to eliminate activated TILs in vivo via Fas/FasL-
induced apoptosis or other hitherto unknown mechanisms.
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1994; De Maria et al, 1996). The activated TILs are likely to
express FasL and, unless they are selectively eliminated or FasL—,
they might increase the frequency of FasL detection in the primary
or metastatic carcinomatous tissue. In the present work, these
caveats were taken into account and the validity of the ￿counter-
attack model￿ was investigated in more detail in vivo. FasL mRNA
and protein expression was analysed in paired tissue samples from
normal colonic mucosa, primary CRCs and the metastases from a
total of 21 patients. Additionally, we examined the presence and
activation status of TILs in the same tissue samples. All applied
methods led to more frequent detection of FasL in metastases of
CRC than in their primary carcinomas. Simultaneously, the
number of activated TILs in the metastases was lower than in the
primary tumours. The increased frequency of detection of FasL
and the decreased number of activated TILs in metastases support
the ￿counterattack model￿ in vivo.
MATERIALS AND METHODS
Cell lines
Human colonic adenocarcinoma cell lines HT29, LS174T, CaCo2,
Colo 201, Colo 205, Colo 206, SW 403, SW 480, SW 620 and T84
were obtained from the American Type Culture Collection. Cell
lines HCA7, LS 1034, JWI and CCO7 were kindly provided by W
Bodmer, International Cancer Research Fund, London, UK. Troja
1 and Troja 2 cell lines were derived from hepatic metastases of
CRC as described previously (Kemmner et al, 1987). All cell lines
were cultured under standard conditions.
Patient tissue samples
Tissue samples from primary colorectal carcinomas, their liver
metastases and specimens of normal colonic mucosa (taken at a
distance of 10 cm from the tumour) were obtained at the time of
surgery from 13 patients with UICC stage IV CRC. Total RNA
was immediately isolated from samples of ten patients and protein
lysates from samples from six patients. Tissue samples from
normal liver was obtained from four patients. Samples of normal,
tumour and metastatic tissues from 12 patients (all UICC stage IV)
were fixed in 3.7% formalin and embedded in paraffin.
RNA isolation
Total RNA was extracted from the tissue samples, without
previous freezing or storage, with guanidinium thiocyanate
followed by centrifugation in caesium chloride as described by
Sambrook et al (1989) and from cell lines with RNAzol (Biotex
Laboratories, Houston, TX, USA) according to the recommenda-
tions of the manufacturer.
cDNA synthesis
DNase digestion of total RNA was performed prior to cDNA
synthesis to rule out contamination with genomic DNA. Twenty
micrograms of total RNA was incubated for 2 h in 37°C with
200 U RNase-free DNase I (Boehringer, Mannheim, Germany)
diluted in DEPC-water to a final volume of 50 ml containing
50 mM Tris-HCl (pH 6.5), 10 mM magnesium chloride, 10 mM
dithiothreitol (DTT) (Gibco BRL, Karlsruhe, Germany) and 20 U
of RNase inhibitor (Boehringer, Mannheim, Germany). After
denaturation, 2.5 mg of DNase-digested RNA was hybridized with
2.5 ml of random hexanucleotide primers (Gibco BRL, Karlsruhe,
Germany) and diluted to a final volume of 22 ml in DEPC-water in
70°C for 10 min. After hybridization, the sample was cooled on
ice and 28 ml of mastermix was added, containing 10 ml of 5 ´
transcriptase buffer (Gibco), 10 ml of dinucleotide triphosphate
(dNTP) mix (2.5 mM each), 5 ml of 0.1 mM DTT, 20 U of RNase
inhibitor and 500 U of reverse transcriptase (Superscript, Gibco),
resulting in a final volume of 50 ml followed by a 1-h incubation at
37°C. The reaction was terminated by boiling for 10 min.
Primers
The purity and quantity of cDNA were determined in RT-PCR
with primers detecting pyruvate dehydrogenase (PDH). PDH
forward primer, 5¢-GGT ATG GAT GAG GAG CTG GA-3¢, is
located in exon 1, PDH reverse primer, 5¢-CTT CCA CAG CCC
TCG ACT AA-3¢, is located in exon 2. Consequently, a cDNA
amplimer of 103 bp was detected, whereas amplification of
genomic DNA contamination resulted in a PCR product of
185 bp. For Fas detection, forward primer, 5¢-GAA ATG AAA
TCC AAA GCT-3¢ (bp 1177—1196), and reverse primer, 5¢-TAA
TTT AGA GGC AAA GTG GC-3¢ (bp 1645—1626), were used,
resulting in a 469-bp amplimer. FasL forward primer was 5¢-GGA
TTG GGC CTG GGG ATG TTT CA-3¢ (bp 474—496) and FasL
reverse primer 5¢-TTG TGG CTC AGG GGC AGG TTG TTG-3¢
(bp 817—794), giving a PCR product of 344 bp length. As a marker
for the presence of lymphocytes in the tissue samples, CD3 was
detected in RT-PCR using CD3 forward primer, 5¢-GGC TGT
CCT CAT CCT GGC TAT CAT-3¢ (bp 21—44), and CD3 reverse
primer, 5¢-ACT GGT TTC CTT GAA GGT GGC TGT-3¢ (bp
535—512), resulting in a specific amplimer of 515 bp. The activa-
tion status of resting T-cells was analysed by detecting CD25 with
forward primer 5¢ TTC CAG GTG AAG AGA AGC CTC AGG 3¢
(bp 521—544) and reverse primer 5¢ TCT GTT CCC GGC TTC
TTA CCA AGA 3¢ (bp 807—784) and giving an amplimer of 287
bp length. Primer pairs for Fas and CD25 were created and tested
for specificity in the HUSAR¤ program; primer pairs for FasL
and CD3 have been described previously (O￿Conell et al, 1996;
James-Yarish et al, 1994). All primers were obtained from TIB
MOLBIOL Syntheselabor, Berlin, Germany.
RT-PCR
For every RT-PCR, 20 mg total RNA was reverse transcribed in
50 ml volume as described. Two per cent of the newly synthesized
cDNA (1 ml) was added to a 24-ml reaction mixture containing
2.5 ml of a 10 ´ reaction buffer [100 mM Tris-HCl (pH 8.8), 500 mM
potassium chloride and 0.8% Nonidet P40] and 15 mM magnesium
chloride (MBI Fermentas, Vilnius, Lithuania), 0.75 ml of a dNTP
mixture containing 10 mM dNTP, 10 pmol of each primer and
0.5 U of Taq polymerase (MBI, Fermentas). The mixture was
overlaid with 50 ml of mineral oil to prevent evaporation. PCR was
initiated in a thermal cycler (Omnigene, Hybaid, MWG-Biotech,
Germany) and programmed for the following cycle parameters:
one cycle of 95°C for 2 min; 35 cycles of 95°C for 45s, 58°C for
45s and 72°C for 1 min; and one cycle of 72°C for 5 min. Fas PCR
was performed by adding 2 ml of cDNA to a 23-ml reaction
mixture as above apart from a differing magnesium chloride
FasL expression in metastases of colorectal carcinomas 1263
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concentration of 9 mM. The PCR programme for Fas was 95°C,
1 min, 60°C, 1 min, 72°C, 1 min, 40 cycles and 72°C, 5 min,
1 cycle. For FasL PCR, 2.5 ml of template was used in 22.5 ml reac-
tion mixture identical to that of PDH PCR, but with an increased
amount of Taq polymerase of 1.25 U. Cycle parameters were 95°C,
2 min 1 cycle; 94°C, 45 sec, 65°C, 1 min, 72°C, 1 min, 40 cycles
and 72°C, 5 min, 1 cycle. CD3 and CD25 PCR was performed as
hot start procedures. One ml of cDNA template was added to 44 ml
of reaction mixture containing 5 ml of 10 ´ reaction buffer (1.5 mM
magnesium chloride), 1 ml of dNTP mix and 20 pmol of each
primer. The mixture was heated to 95°C for 5 min, allowed to cool
to 80°C and then mixed with 1 U of polymerase. RT-PCR parame-
ters for both CD3 and CD25 were 95°C for 1 min, 58°C for 1 min
and 72°C for 2 min (40 cycles for CD3 and 30, 35, 40 and
45 cycles for CD25) with one final cycle of 72°C for 5 min. The
PCR products were separated by electrophoresis on a 1.5% agarose
gel and visualized by ethidium bromide staining. The intensity of
the specific bands were estimated as absent (—), weakly positive
(±), positive (+) or strongly positive (++).
In situ hybridization
For in situ hybridization, 5-mm-thick sections of paraffin-
embedded tissues were collected on ChemMateTM slides (Dako
Diagnostika, Hamburg, Germany). The probe was generated by
amplification of cDNA from the anaplastic large-cell lymphoma
cell line Karpas 299 (Foss et al, 1997) using primers specific for
the FasL sequence. The obtained fragment (820 bp, ranging from
base 67 to base 886) was cloned in the vector pTAQ (R&D
Systems, Wiesbaden, Germany). The sequence of the probe deter-
mined on the DNA sequencer 373 A (Applied Biosystems, Foster
City, CA, USA) was identical to the FasL sequence. After
linearization of the plasmids, the cRNA probes were obtained by
run-off transcription using the T7 RNA polymerase with incorpo-
ration of [35S]UTP (1300 Ci mmol—1, NEN, Bad Homburg,
Germany). Alkaline hydrolysis was performed for 50 min to
generate cRNA fragments of 100—150 bp in length. For in situ
hybridization, dewaxed and rehydrated paraffin sections were
exposed to 0.2 N hydrochloric acid and 0.5 mg ml—1 Pronase
(Boehringer—Mannheim, Germany), acetylated with 0.25% acetic
anhydride in 0.1 M triethanolamine pH 8.0 and dehydrated through
graded ethanol solutions. Slides were hybridized with 4 ´ 105 cpm
of the labelled probe (specific radioactivity 8 ´ 106 cpm  mg—1
RNA). Prehybridization, hybridization, removal of non-specifi-
cally bound probe by RNase digestion and washing procedures
were performed as described previously (Foss et al, 1997).
Autoradiography was performed by dipping the dehydrated slides
in Amersham nuclear emulsion (Amersham, Braunschweig,
Germany) and exposing for 100 days. The staining of cells was
scored by three independent observers for intensity as — (identical
to the background), + (2 ´ stronger than the background) and ++
(more than 2 ´ stronger than the background).
Immunohistochemistry
Paraffin-embedded sections (4 mm) were deparaffinized in xylene
and rehydrated through graded alcohols into phosphate-buffered
saline (PBS). Heat-induced epitope retrieval was achieved by
immersion of slides in 10 mM citrate buffer (pH 6.0) and boiling
for 10 min in a pressure cooker, followed by cooling in PBS.
Endogenous peroxidase was blocked by 15 min incubation with
0.6% hydrogen peroxide in methanol. To prevent unspecific
binding, the sections were incubated in 20% inactivated fetal calf
serum in PBS for 30 min. They were then incubated in 0.6 mg ml—1
mouse monoclonal antibody raised to residues 116—277 of human
FasL (Transduction Laboratories, Lexington, KY, USA) overnight
at 4°C. After incubation with a second antibody conjugated to
peroxidase, the development was performed by incubation in a
3,3¢-diaminobenzidine tetrahydrochloride solution. Staining was
scored by two independent observers for intensity as — (negative),
+ (weak), ++ (moderate) and +++ (strong).
Immunoblotting
Whole-cell lysates from cultured cell lines were prepared from
approximately 5 ´ 106 cells in 10 ml of lysis buffer (1% Triton X-
100, 20 mM Tris HCl, 140 mM sodium chloride, 1.5 mM magne-
sium chloride, 1 mM EGTA, 10% glycerol, 10 mg ml—1 DNAase,
1m M sodium vanadate, 50 mM sodium fluoride, 1 mM PMSF,
1m M benzamidine and 10 mg ml—1 each of aprotinin, leupeptin and
pepstatin). Lysates from whole tissue samples were prepared by
pulverization of approximately 1 g wet weight of snap-frozen
tissue under liquid nitrogen and incubation in 10 ml of lysis buffer.
After centrifugation (13 000 ´ g for 30 min) and protein determi-
nation, 5 mg of total protein was electroblotted onto PVDF
membrane following separation on a 12.5% sodium dodecyl
sulphate (SDS)-polyacrylamide gel. Membranes were saturated
for 1 h using 5% dry milk/1% bovine serum albumin (BSA) in
1 ´ PBS and incubated overnight at 4°C with 2.5 mgm l —1 of
anti-human FasL murine monoclonal antibody (Transduction
Laboratories) in the same solution. The membranes were then
incubated for 1 h with a rabbit anti-murine IgG antibody
conjugated to peroxidase (Dako, Hamburg, Germany). The detec-
tion followed with the ECL detection system (Amersham,
Braunschweig, Germany).
Statistical evaluation
The in situ hybridization data were plotted on scatter diagram and
ranked according to the Wilcoxon pair difference test. The differ-
ences in gene expression, determined in RT-PCR for T and M were
analysed by c2-test.
RESULTS
Expression of FasL in cell lines derived from colorectal
carcinomas and metastases
FasL was detected in several cell lines derived from primary
colorectal carcinomas and metastases, at the mRNA level by RT-
PCR and at the protein level by immunoblotting, and the corre-
spondence of the two methods was analysed. FasL expression was
detectable in 6 of 12 cell lines derived from primary colorectal
adenocarcinomas in RT-PCR. Five of these and, additionally, four
further cell lines expressed Fas, i.e. 9 of 12 analysed colorectal
carcinoma cell lines were Fas+. Of four cell lines derived from
colorectal carcinoma metastases only one expressed FasL. This
cell line, SW620, was Fas—, whereas the three other cell lines were
Fas+ (Figure 1).
The expression of FasL mRNA was further tested on protein
level via immunoblotting of lysates from seven cell lines. One of
three carcinoma cell lines (HT 29) that were FasL— in RT-PCRFasL expression in metastases of colorectal carcinomas 1265
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showed a weak band at 37 kDa, specific for FasL (Niehans et al,
1997). The second band at Mr 34 500 is assumed to be a differen-
tially glycosylated form of FasL (Suda et al, 1993). All three carci-
noma cell lines and the metastatic cell line SW620, which were
FasL+ in RT-PCR, showed the specific protein band (Figure 2).
These data indicated a satisfactory correspondence between RT-
PCR and immunoblotting.
Expression and localization of FasL-mRNA and -protein
in patient tissues
To analyse the expression of FasL mRNA in epithelial cells and
lymphocytes in vivo, we performed in situ hybridization with an
antisense FasL probe and immunohistochemistry using anti-
human FasL murine monoclonal antibody.
FasL mRNA as detected by in situ hybridization
In most samples, FasL mRNA was detectable by in situ hybridiza-
tion only after 100 or more days of exposure. The usually weak
signals after this long exposure time indicated that the expression
of FasL mRNA is very low. In the normal colonic mucosa, FasL
mRNA expression was detectable only in one case at the tip of the
crypt. By contrast, in 4 of 12 primary carcinomas FasL-mRNA
expression was detectable in the majority of cells. Of 12 investi-
gated liver metastases six showed expression of FasL mRNA
(Figure 3). In 5 of 12 patients all three tissue types showed no
staining after 100 days of exposure. In the remaining seven
patients, the metastatic tissue stained in one case weaker, in one
case equally strong and in five cases stronger than in the corre-
sponding primary tumour. In both primary and metastatic carcino-
matous tissues, FasL+ TILs were visible. They were, however,
sparse and weakly stained and a difference in their number between
primary carcinomas and liver metastases was not evaluated.
In summary, in situ hybridization permitted the detection of
FasL mRNA in 30% of primary tumours and in 50% of the metas-
tases. TILs also expressed FasL mRNA in primary tumours and in
metastases. These results raised the question of how far activated
TILs contribute to the detectable amounts of FasL in patient tissue
samples when very sensitive methods such as RT-PCR are used.
FasL-protein as detected by immunohistochemistry
Immunohistochemistry with anti-human FasL monoclonal anti-
body was performed in sections of tumours and metastases from
five patients. The staining of positive cells was diffuse and
cytosolic, homogeneously distributed among most epithelial cells
(Figure 4). The normal colonic mucosa stained weakly (4/5) or
moderately (1/5). The primary tumours were stained moderately
(3/5) or strongly (2/5) as were the metastases (2/5 and 3/5 respec-
tively), with no discernible differences between the two groups.
Expression of FasL-protein as detected by
immunoblotting of tissue lysates
In order to quantify FasL protein expression, the lysates from N, T
and M of six patients were analysed by immunoblotting. The
specific bands for FasL were detectable in two out of six lysates
from normal colonic mucosa, in two out of six lysates from
primary tumours and in all lysates derived from metastatic tissue
(Figure 5). In two patients, all three tissues expressed FasL
protein. The intensity of the FasL band was, in one instance in the
primary tumour, stronger and in one instance weaker than in the
metastatic tissue. In summary, in five out of six investigated
patients, the metastatic tissue showed stronger FasL expression
than the corresponding primary tumour. Immunoblotting clearly
showed that the FasL protein expression in normal tissue is rare.
Thus, the weak immunohistochemical staining of the normal
mucosa was interpreted to be due to unspecific binding of the anti-
body to the mucus.
Expression of FasL-mRNA in normal, carcinomatous
and metastatic tissues as detected by RT-PCR
A further refinement of the FasL detection and quantification was
achieved through application of semiquantitative RT-PCR. It was
applied to RNA isolated from N, T and M tissue of ten patients.
Fas mRNA was detected in nine out of ten normal mucosa
samples, in nine out of ten primary carcinomas and in all
metastases, indicating no significant alteration in the frequency of
expression of this gene in colonic tissue during the progression of
carcinogenesis. By contrast, FasL mRNA was detectable in five
out of ten normal tissues, in three out of ten primary carcinomas
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Figure 1 Detection of Fas- and FasL-mRNA in 12 cell lines derived from
human CRC and one melanoma cell line. (A) 1, HT29; 2, LS174T; 3, HCA7;
4, LS1034; 5, JWI; 6, Caco2; 7, Colo201; 8, Colo205; 9, Colo206; 10, CCO7;
11, SW403; 12, SW480; and in four cell lines derived from CRC metastases.
(B) 1, T84; 2, Troja 1; 3, Troja 2; 4, SW620 by RT-PCR. A 344-bp-long FasL-
specific sequence or a 469-bp-long Fas-specific sequence was amplified
from cDNA, separated on agarose gel and visualized by ethidium bromide
staining. RT-PCR of PDH was performed to verify that the amounts of RNA
used were similar
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Figure 2 Immunoblot of 5 mg of protein of whole-cell lysates isolated from
six cell lines derived from human primary CRC (T) and one cell line derived
from CRC metastases (M) separated on 12.5% gel, blotted and detected
with anti-human FasL MAb. 1, HT 29; 2, LS174T; 3, HCA7; 4, CCO7; 5,
Colo205; 6, SW480; 7, SW620. Detection with anti-human b-actin MAb was
performed to verify that the amounts of protein used were similar1266 B Mann et al
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and in nine out of ten liver metastases. In the four investigated
samples of normal liver tissue, Fas mRNA was detected in all and
FasL mRNA weakly in three samples (data not shown).
The reverse transcription was carried out with the same amount
of RNA from every tissue and the PCR followed with 40 cycles.
The semiquantitative evaluation of the specific bands obtained
under these standarized conditions indicated that the expression of
FasL was stronger in the metastases than in the primary tumours
in nine out of ten cases (Table 1 and Figure 6). Thus, FasL gene
expression was significantly more frequent (P< 0.01) in the
metastatic than in the primary carcinomatous colonic tissue.
Comparison of FasL mRNA and -protein detection by
four methods
The results obtained by the four methods are summarized in Table 2.
They indicate that in the normal colonic tissue FasL mRNA is
expressed at a very low level and, if the most sensitive method
(RT-PCR) is applied, it is detectable in 50% of the samples. In
tumour tissue, expression occurs in about 30—40% of cases. In
matched liver metastases, FasL was detected most frequently by
all methods. The highest frequency of detection was associated
with increased amounts of FasL mRNA (Figure 6 and Table 1) and
protein (Figure 5) in the metastatic tissue.
N
T
M
Figure 3In situ hybridization of FasL mRNA on paraffin-embedded
sections of normal colonic mucosa (N), primary carcinoma (T) and a liver
metastasis (M) with FasL antisense probe (see Materials and methods).
Counterstaining with haematoxylin–eosin. Bar, 50mm
N T
M
Figure 4Immunohistochemistry with anti-human FasL MAb on paraffin-
embedded sections of a primary carcinoma (T), the adjacent nondysplastic
mucosa (N) and a liver metastasis (M). Bar, 100mm. A parallel section in
which the first antibody was omitted showed no staining. A section of the
anterior eye chamber was used as a positive control (data not shown)FasL expression in metastases of colorectal carcinomas 1267
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Presence and activation status of infiltrating
lymphocytes in patients’ tissues
The more frequent detection of FasL mRNA and protein in the
metastatic tissue prompted the question of how far the detected
FasL expression is due to the presence of activated FasL+ TILs.
CD3 mRNA, used as a marker of T cells, was detectable by RT-
PCR in nine out of ten samples of N and in all samples of T and M
(Figure 6) confirming the previous data on the presence of T cells
in these tissues (Shimizu et al, 1992; ﬂstenstad et al, 1994; De
Maria et al, 1996). The mRNA of the T-cell activation marker
CD25 was detected in three out of ten N samples, in all T samples
and in five out of ten metastases after the standard RT-PCR proce-
dure including 40 cycles of PCR. The difference in the frequency
of CD25 detection between T and M was significant (P < 0.01). In
order to analyse further how far this difference is attributable to the
different amounts of CD25 mRNA present in total mRNA from
the different tissue groups, we performed a RT-PCR of CD25
mRNA in all samples with 30, 35, 40 and 45 cycles, keeping all
other parameters constant. The percentage of samples in which
CD25 mRNA was detectable increased with increased number of
cycles in PCR, and at 45 cycles it reached 80—100% in all samples
(Figure 7).
These data indicated that activated T cells are present in all
investigated tissues. They suggest, further, that the amount of
CD25 mRNA was higher in the primary tumours than in the
normal colonic mucosa or metastases. This conclusion is
supported by (1) the stronger intensity of the CD25 amplimer
bands obtained after 40 PCR cycles from primary tumours than
from the paired metastases (Table 1 and Figure 6) and (2) the more
frequent detection of CD25 mRNA in primary tumours than in
metastases after the same number of cycles (Figure 7). A higher
percentage of activated T cells in carcinomatous tissues than in
normal colonic mucosa was also detected previously by FACS
analysis (ﬂstenstad et al, 1994; De Maria et al, 1996). From these
data, we conclude that in 50% of patients the number of activated
lymphocytes present in the metastatic tissue was lower than in the
primary tumour of similar weight. The increased frequency of
detection of FasL in the same metastatic tissues is not, therefore,
attributable to the increased number of activated T cells.
DISCUSSION
The ￿counterattack model￿ suggesting that tumour cells can induce
apoptosis of cytotoxic T cells via Fas/FasL death signal, is based on
in vitro data, which have shown that different FasL+ tumour cells
are able to kill Jurkat cells in co-culture experiments. It was
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Figure 5 Immunoblot of 5 mg of protein of lysates obtained from 1 g of
normal colonic mucosa (N), primary tumours (T) and metastases (M) from
five patients, separated on 12.5% gel, blotted and detected with a-human
FasL MAb. Detection with anti-human b-actin MAb was performed to verify
that the amounts of protein used were similar
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Figure 6 Detection of Fas, FasL, CD3 and CD25 mRNA in tissue samples
from normal colonic mucosa (N), primary carcinomas (T) and their liver
metastases (M) by RT-PCR. Specific sequences for each gene were
amplified from cDNA, separated on agarose gel and visualized by ethidium
bromide staining. RT-PCR of CD3-mRNA was used to detect T cells in the
tissue samples; RT-PCR of CD25 mRNA was used to analyse their
activation status. RT-PCR of PDH was performed to verify that the amounts
of RNA used were similar. Results from five patients out of ten investigated
(Table 1) are shown
Table 1 Detection of FasL and CD25 mRNA by means of RT-PCR in paired samples of normal colonic mucosa (N), primary carcinomas (T) and
liver metastases (M) from ten patients. RT-PCR was carried out for 40 cycles. The intensity of the amplimer bands was semiquantitatively
estimated after ethidium bromide staining. The change in the intensity of amplimer bands for each gene was additionally evaluated within the
paired M and T samples (M vs. T) and the extent of increase (­) or decrease (¯) was estimated (nc, not changed). The PDH band had a similar
intensity (++) in all samples. The representative electrophoresis results are shown in Figure 6
N T M M vs. T
Patient no. FasL CD25 FasL CD25 FasL CD25 FasL CD25
201 – ± –+ + + – ­¯ ¯
209 ± – – ++ ++ ±­ ­¯
212 + – – ++ + + ­¯
214 + + + + ++ + ­ nc
223 ± –– + + ± – ­¯ ¯
229 + – – ++ ++ – ­­ ¯¯
232 – – – ++ – + nc ¯
233 – – ± ++ ++ – ­¯ ¯
234 – – – ++ ± – ­¯ ¯
238 – + + ++ ++ ±­¯
Total detectable 5/10 3/10 3/10 10/10 9/10 5/10 9/10 ­ 9/10¯1268 B Mann et al
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hypothesized that an analogous mechanism facilitating the progres-
sion of the carcinomas is operative in vivo. The main goal of the
present work was to test this hypothesis by analysing the expression
of FasL mRNA and protein during the progression of CRC.
We detected Fas mRNA in 9 out of 12 cell lines derived from
primary CRC and in three out of four metastatic cell lines. Thus, a
considerable percentage of tumour- and metastasis-derived cell
lines should be susceptible to FasL-mediated apoptosis. In patient
tissues, Fas mRNA was detected in almost all samples in all three
tissue types. Previous immunhistochemical data have shown,
however, that colon carcinoma tissue expresses less Fas than
normal colonic mucosa. This down-regulation may protect some
tumour cells from killing by apoptosis (M￿ller et al, 1994).
FasL was detected in 6 out of 12 investigated cell lines derived
from primary colorectal carcinomas. A similar result was obtained
by other authors, who detected FasL in about 50% of investigated
colon carcinoma cell lines (O￿Connell et al, 1996; Arai et al, 1997;
Shiraki et al, 1997). The RT-PCR data at the protein level were
confirmed by immunoblotting of whole-cell lysates. The low
percentage of FasL+ cell lines derived from metastases (one of
four) detected in the present work was surprising and did not
support the hypothesis of preferential expression of FasL in
metastatic cells; the number of available cell lines is, however, too
low to yield statistically significant data. It is of interest that only
the FasL+ metastatic cell line SW620 expressed no detectable Fas,
i.e. it was resistant to FasL-mediated apoptosis.
In vivo, FasL was detectable in about 10—30% of the normal
mucosa samples in immunoblots, by immunhistochemistry and in
situ hybridization. Using RT-PCR, a more sensitive method, we
found FasL mRNA in 50% of samples of normal mucosa, in 30%
of the primary tumours and in 90% of the corresponding metas-
tases. With the four methods used for analyses of FasL mRNA and
protein in patient tissues, the percentage of FasL+ samples varied
in primary tumours between 30% and 40% and in metastases
between 50% and 100%. However, all procedures yielded a higher
frequency of FasL detection in the metastases than in the primary
tumours. This difference was significant when RT-PCR, the most
sensitive method, was used (Table 2). Thus, the situation in cell
lines derived from metastases does not reflect the findings found in
metastatic tissue samples by us and others. This might be due to
the complex cytokine environment and the presence of co-stimula-
tory factors, which may induce FasL expression in vivo but are
missing in cell cultures, or to other FasL+ cells in the tissue.
The question of how far the activated TILs contribute to the
detected amounts of FasL was addressed by analysing the
expression of CD3 and CD25 in all samples. CD3 mRNA was
detectable in almost all specimens of the normal colon and in all
carcinomas and metastases, as expected from previous FACS
data (Shimizu et al, 1992; ﬂstenstad et al, 1994; De Maria et al,
1996). The amount of CD25 mRNA marking the activated
subpopulation of T cells was considerably higher in the primary
carcinomas than in the normal colonic mucosa (Table 1 and
Figures 6 and 7). This finding corroborates reports that show in
FACS analysis a higher percentage of activated T cells in
primary colorectal carcinomas than in normal mucosa (ﬂstenstad
et al, 1994; De Maria et al, 1996). In liver metastases, the amount
of CD25 mRNA was in nine out of ten samples lower than in the
paired primary carcinomas and was similar to the amount in
normal tissue. Assuming that the CD25 amounts correctly reflect
the number of activated TILs in the three tissues, these data
suggest that the number of activated TILs in M is frequently
lower than in T; they either infiltrate the metastases less effi-
ciently than the primary tumours or are eliminated in the
metastatic tissue by FasL-mediated apoptosis or other mecha-
nisms. The concomitant, more frequent, FasL expression in the
metastases suggests that the detection of FasL mRNA in the
metastatic tissue samples indeed represents expression on the
metastatic tumour cells and is not due to increased presence of
activated TILs.
In FasL+ tumours, there seems to be a potentially lethal
reciprocal interaction; both tumour cells and activated TILs are
expressing Fas and FasL and, therefore, both have the ability to act
either as effectors or as targets in Fas/FasL-mediated killing. Thus,
the survival of the tumour or the host cells may depend on which
cells can accomplish which task more efficiently. Fas+ tumours are
potentially susceptible to FasL-mediated killing. It has been shown
in vitro, however, that Fas+ tumour cells may fail to respond to
FasL signal with apoptosis (O￿Connell et al, 1996). More impor-
tantly, in tumour or metastatic tissue, tumour cells greatly
outnumber the TILs. This disproportion increases the probability
that tumour cells may kill the cytotoxic T lymphocytes rather than
the reverse, as shown recently by Zeytun et al (1997) for
lymphoma cells in vitro. This hypothesis of deletion of tumour-
reactive T cells via Fas—FasL interaction could explain why the
amount of CD25 antigen found in the metastases was lower than in
the tumours.
This notion is further supported by the results of Hahne et al
(1996), who observed that FasL+ tumours grow faster in Fas+ than
in Fas— mice. In other model systems, however, FasL expression on
tumour cells, including colorectal carcinomas, does not facilitate
tumour growth but induces tumour rejection, mediated mainly by
neutrophils (Arai et al, 1997; Seino et al, 1997). When FasL+
pancreatic islet cells were injected into allogeneic hosts, they did
not induce apoptosis of the infiltrating T cells but were destroyed
N
T
M
30 35 40 45
Number of PCR cycles
C
D
2
5
+
 
s
a
m
p
l
e
s
 
(
%
)
100
80
60
40
20
0
Figure 7 Percentage of CD25+ samples determined in RT-PCR after 30, 35,
40 and 45 cycles in normal colonic tissue (N), primary tumours (T) and liver
metastases (M) (each n = 10).
Table 2 Frequency of FasL+ samples in normal colonic mucosa (N), primary
carcinomas (T) and liver metastases (M) determined by four different
methods. Only strongly stained samples (+++) in the immunohistochemistry
group were included
Detection method N T M
Immunohistochemistry 0/5 2/5 3/5
Immunoblotting 2/6 2/6 6/6
In situ hybridization 1/12 4/12 6/12
RT-PCR 5/10 3/10 9/10FasL expression in metastases of colorectal carcinomas 1269
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by neutrophilic granulocytes (Kang et al, 1997). Furthermore, T
cells activated by viral infection are not susceptible to FasL-
mediated cell death in vivo (Ehl et al, 1996). Taken together, these
results suggest that FasL-expressing cells can prevent immune
response by inducing cell death of activated lymphocytes, and this
may be the case in colon carcinoma metastases. Alternatively,
FasL+ cells may induce potent granulocytic inflammatory
response, and it was hypothesized recently that this induction is
mainly attributable to soluble FasL (Strasser and O￿Connor, 1998).
The factors necessary for this reaction are apparently not present
in sufficient amounts in the tumour and metastatic tissue because
acute granulocytic inflammation is only rarely observed in these
tissues. This may be due to a number of mechanisms that suppress
the lymphocyte activation in tumour tissues, such as low number
of dendritic cells in the tumour (Ambe et al, 1989), reduced IL-4
and TNF-a expression (Barth et al, 1996) or the loss of the z-chain
of the T-cell receptor and granzyme B-mRNA in TILs of human
CRC (Mulder et al, 1997). These defects in TILs may additionally
enhance their susceptibility to FasL-mediated apoptosis and
suppress the inflammatory reaction.
In summary, we showed by four different methods that the
frequency of FasL mRNA and protein expression in liver metas-
tases of human colorectal cancers is higher than in their primary
carcinomas. Simultaneously, the number of activated TILs is
decreased in these metastatic tissues. We conclude that FasL
expression could give metastasizing subpopulations of CRC a
growth advantage and might facilitate metastatic growth in distant
organs. This might be attributable to elimination of activated TILs
via Fas/FasL induced apoptosis or to other hitherto unknown
mechanisms.
ACKNOWLEDGEMENT
This work was supported by DFG, Proj. No. Ma-1989 1/1,
Deutsche Krebshilfe 10-1025-HaI and Sonnenfeld Stiftung.
REFERENCES
Ambe K, Mori M and Enjoji M (1989) S-100 protein positive dendritic cells in
colorectal adenocarcinomas. Cancer 63: 496—503
Arai H, Gordon D, Nabel EG and Nabel GJ (1997) Gene transfer of Fas
ligand induces tumour regression in vivo. Proc Natl Acad Sci USA 94:
13862—13867
Barth RJ, Camp BJ, Martuscello TA, Dain BJ and Memoli VA (1996) The cytokine
microenvironment of human colon carcinoma. Cancer 78: 1168—1178
Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A and Duke RC (1995) A role
of CD95 ligand in preventing graft rejection. Nature 377: 630—632
Brunner TH, Mogli RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ,
Force WR, Lynch DH, Ware CF and Green DR (1995) Cell autonomous
Fas/Fas-ligand interaction mediates activation-induced apoptosis in T-cell
hybridomas. Nature 373: 441—444
De Maria R, Boirivant M, Cifone MG, Roncaioli P, Hahne M, Tschopp J, Pallone F,
Santoni A and Testi R (1996) Functional expression of Fas and Fas Ligand on
human gut lamina propria T lymphocytes. J Clin Invest 97: 316—322
Dhein J, Walczak H, B￿umler C, Debatin KM and Krammer PH (1995) Autocrine
T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373: 438—441
Ehl S, Hoffmann-Rohrer U, Nagata S, Hengartner H and Zinkernagel R (1996)
Different susceptibility of cytotoxic T-cells to CD95 ligand-mediated cell death
after activation in vitro vs in vivo. J Immunol 156: 2357—2360
Foss HD, Demel G, Anagnostopoulos I, Aranjo I, Hummel M and Stein H (1997)
Uniform expression of cytotoxic molecules in anaplastic large cell lymphoma
of Null/T-cell phenotype and in cell lines derived from anaplastic large cell
lymphomas. Pathobiology 65: 83—90
French LE and Tschopp J (1996) Constitutive Fas Ligand expression in several non-
lymphoid mouse tissues and implications for immune-protection and cell
turnover. Behring Inst Mitt 97: 156—160
French LE, Hahne M, Vicard I, Radlgruber G, Zanone R, Becker K, M￿ller C and
Tschopp J (1996) Fas and Fas ligand in embryos and adult mice: ligand
expression in several immune privileged tissues and coexpression in adult
tissues characterized by apoptotic cell turnover. J Cell Biol 133: 335—343
Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH
and Runkel L (1995) Involvement of the CD95 receptor and ligand in liver
damage. J Exp Med 182: 1223—1230
Griffith TS, Brunner TH, Fletcher SM, Green DR and Ferguson TA (1995) Fas
ligand induced apoptosis as a mechanism of immune privilege. Science 270:
1189—1192
Hahne M, Rimoldi D, Schr￿ter M, Romero P, Schreier M, French LE, Schneider P,
Bornand T, Fontana A, Lienard D, Cerottini JC and Tschopp J (1996)
Melanoma cell expression of Fas(Apo-1/CD95) Ligand: implications for
tumour immune escape. Science 274: 1363—1366
James-Yarish M, Bradley WG, Emmanuel PJ, Good RA and Day NK (1994)
Detection of cell specific cluster determinant expression by reverse
transcription polymerase chain reaction. J Immunol Meth 169: 73—82
Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG and Baekkeskov
S (1997) Fas ligand expression in islets of Langerhans does not confer immune
privilege and instead targets them for rapid destruction. Nature Med 3:
738—743
Kemmner W, Schlag P and Brossmer R (1987) A rapid and simple procedure for
dissociation of tumour tissue from the human colon. J Cancer Res Clin Oncol
113: 400—401
M￿ller P, Koretz K, Leih￿user F, Br￿derlein S, Henne C, Quentmeier A and
Krammer PH (1994) Expression of APO-1 (CD95), a member of the NGF/TNF
receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer
57: 371—377
Mulder WMC, Bloemena E, Stukart MJ, Kummer JA, Wagstaff RJ and Scheper RJ
(1997) T-cell receptor-zetta and granzyme B expression in mononuclear cell
infiltrates in normal colonic mucosa and colon carcinoma. Gut 40: 113—119
Nagata S and Golstein P (1995) The Fas death factor. Science 267: 1449—1456
Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno T, Knapp DJ, Green DR and
Kratzke RA (1997) Human lung carcinomas express Fas-ligand. Cancer Res
57: 1007—1012
O￿Connell J, Sullivan GC and Collins JK (1996) The Fas counterattack: Fas-
mediated T-cell killing by colon cancer cells expressing Fas-Ligand. J Exp Med
184: 1075—1082
Oshimi Y, Oda S, Honda Y, Nagata S and Miyazaki S (1996) Involvement of Fas
Ligand and Fas mediated pathway in the cytotoxicity of human natural killer
cells. J Immunol 157: 2909—2915
ﬂstenstad B, Lea T, Schlichting E and Harboe M (1994) Human colorectal tumour
infiltrating lymphocytes express activation markers and the CD45R0 molecule,
showing a primed population of lymphocytes in the tumour area. Gut 35:
382—387
Sambrook J, Fritsch EF and Maniatis T (1989) Molecular Cloning, a Laboratory
Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY
Seino KI, Kayagaki N, Okumura K and Yagita H (1997) Antitumour effect of locally
produced CD95 ligand. Nature Med 3: 165—170
Shimizu Y, Watanabe A and Whiteside TL (1992) Memory T-lymphocytes are the
main population of tumour infiltrating lymphocytes obtained from human
primary liver tumours. J Hepatol 16: 197—202
Shiraki K, Tsuji N, Shioda T, Isselbacher J and Takahashi H (1997) Expression of
Fas-ligand in liver metastases of human colonic adenocarcinomas. Proc Natl
Acad Sci USA 94: 6420—6425
Strand S, Hofmann WJ, Hug H, M￿ller M, Otto G, Strand D, Mariani SM, Stremmel
W, Krammer PH and Galle PR (1996) Lymphocyte apoptosis induced by CD95
(APO-1/Fas) ligand-expressing tumour cells — a mechanism of immune
evasion? Nature Med 2: 1361—1366
Strasser A and O￿Connor L (1998) Fas ligand — caught between scylla and
charybdis. Nature Med 4: 21—23
Suda T, Takahashi T, Golstein P and Nagata S (1993) Molecular cloning and
expression of FasL, a novel member of the tumor necrosis factor family. Cell
75: 1169—1178
Walker PR, Saas P and Dietrich PY (1997) Role of FasL in immune escape — the
tumour cell strikes back. J Immunol 158: 4521—4524
Zeytun A, Hassuneh M, Nagarkatti M and Nagarkatti PS (1997) Fas—Fas ligand-
based interactions between tumour cells and tumour-specific cytotoxic T
lymphocytes: a lethal two-way street. Blood 90: 1952—1959